An AI tool using echocardiograms accurately screens for cardiac amyloidosis, outperforming traditional detection methods.
Key Details
- 1AI model analyzes echocardiogram (ultrasound) images to screen for cardiac amyloidosis.
- 2Developed by Mayo Clinic and Ultromics; validated in a global, multi-ethnic cohort across 18 hospitals.
- 3Achieved 85% sensitivity and 93% specificity in detecting or ruling out cardiac amyloidosis.
- 4Outperformed existing clinical scoring systems for early diagnosis.
- 5FDA-cleared and already being implemented in multiple US hospitals.
Why It Matters
Early, accurate identification of cardiac amyloidosis is critical due to effective therapies available only at earlier disease stages. AI-based screening of routine cardiac ultrasound could substantially improve detection rates and patient outcomes, supporting broader integration of imaging AI in clinical care.
Source
EurekAlert
Related News
•EurekAlert
NIH-Backed AI Model Predicts Cancer Survival Using Single-Cell Data
Researchers have developed scSurvival, a machine learning tool that uses single-cell tumor data to accurately predict cancer patient survival and identify high-risk cell populations.
•EurekAlert
AI Pathology Model Outperforms PD-L1 in Predicting NSCLC Immunotherapy Response
MD Anderson's Path-IO machine learning platform accurately predicts immunotherapy responses in metastatic non-small cell lung cancer, surpassing current biomarker standards.
•EurekAlert
Deep Learning Pathomics Platform Improves Immunotherapy Prediction in Lung Cancer
A deep learning pathomics platform accurately predicts immunotherapy response in metastatic NSCLC using routine pathology slides.